Over a period of 10 years, the continuous monitoring of cardiac iron levels and a tailored chelation therapy allowed a reduction of myocardial iron overload (MIO) in the 70% of patients with thalassemia major (TM) enrolled in the MIOT (Myocardial Iron Overload in Thalassemia) Network. A consequent improvement of cardiac function and a reduction of heart failure were detected. So, a national networking was effective in improving the care and reducing cardiac outcomes of TM patients.
This abstract and the presentation materials are available to members only; a login is required.